Literature DB >> 1534488

Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin.

J H Griffin1, A Gruber, J A Fernández.   

Abstract

The levels of total, free, and bound protein S and C4BP were determined using enzyme-linked immunosorbent assays (ELISAs) in plasma samples (8 males and 8 females) that were individually subjected to immunoadsorption studies in which "free protein S" was defined as that not adsorbed by anti-C4BP antibody-Sepharose column and "free C4BP" as that not adsorbed by anti-protein S antibody-Sepharose. Bound species were calculated as the difference between total and free species. Free protein S (131 nmol/L) averaged 38% of total protein S (346 nmol/L) and free C4BP (37 nmol/L) averaged 14% of total C4BP (264 nmol/L) in plasma. There was an excellent correlation between bound protein S and bound C4BP with 1:1 molar stoichiometry and a good correlation between free protein S antigen and protein S anticoagulant activity. It appears that free protein S is a necessary consequence of the molar excess of protein S over C4BP. C4BP beta chain antigen levels, measured using a new ELISA, averaged 218 nmol/L, a value indistinguishable from the molar concentrations of bound protein S (215 nmol/L) and bound C4BP (227 nmol/L). The free C4BP beta chain antigen was only 4 nmol/L compared with 131 nmol/L free protein S. These results suggest that free C4BP in plasma predominantly lacks the beta chain, that almost all C4BP capable of binding protein S is associated with protein S, and that the plasma levels of oligomeric forms of C4BP containing a beta chain (alpha 7 beta and alpha 6 beta) that bind protein S directly and stoichiometrically regulate free protein S levels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534488

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  Protein C anticoagulant and cytoprotective pathways.

Authors:  John H Griffin; Berislav V Zlokovic; Laurent O Mosnier
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

2.  Genetic determinants of variation in the plasma levels of the C4b-binding protein (C4BP) in Spanish families.

Authors:  Jorge Esparza-Gordillo; José Manuel Soria; Alfonso Buil; Joan Carles Souto; Laura Almasy; John Blangero; Jordi Fontcuberta; Santiago Rodríguez de Córdoba
Journal:  Immunogenetics       Date:  2003-02-22       Impact factor: 2.846

3.  Anti-human protein S antibody induces tissue factor expression through a direct interaction with platelet phosphofructokinase.

Authors:  Changyi Chen; Dan Liao; Jing Wang; Zhengdong Liang; Qizhi Yao
Journal:  Thromb Res       Date:  2013-11-16       Impact factor: 3.944

4.  C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies.

Authors:  Alfonso Buil; David-Alexandre Trégouët; Juan Carlos Souto; Noémie Saut; Marine Germain; Maxime Rotival; Laurence Tiret; Françcois Cambien; Mark Lathrop; Tanja Zeller; Marie-Christine Alessi; Santiago Rodriguez de Cordoba; Thomas Münzel; Philipp Wild; Jordi Fontcuberta; France Gagnon; Joseph Emmerich; Laura Almasy; Stefan Blankenberg; José-Manuel Soria; Pierre-Emmanuel Morange
Journal:  Blood       Date:  2010-03-08       Impact factor: 22.113

5.  Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.

Authors:  Sara Calzavarini; Raja Prince-Eladnani; François Saller; Luca Bologna; Laurent Burnier; Anne C Brisset; Claudia Quarroz; Maria Desiré Reina Caro; Vladimir Ermolayev; Yasuhiro Matsumura; José A Fernández; Tilman M Hackeng; John H Griffin; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2020-05-28       Impact factor: 22.113

6.  Conformational changes in activated protein C caused by binding of the first epidermal growth factor-like module of protein S.

Authors:  T M Hackeng; S Yegneswaran; A E Johnson; J H Griffin
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

Review 7.  New biological concepts on coagulation inhibitors.

Authors:  N Sala; J Fontcuberta; M L Rutllant
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

8.  Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency.

Authors:  Elisabetta Castoldi; Lisbeth F A Maurissen; Daniela Tormene; Luca Spiezia; Sabrina Gavasso; Claudia Radu; Tilman M Hackeng; Jan Rosing; Paolo Simioni
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

9.  Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex.

Authors:  Atsuo Suzuki; Naomi Sanda; Yuhri Miyawaki; Yuta Fujimori; Takayuki Yamada; Akira Takagi; Takashi Murate; Hidehiko Saito; Tetsuhito Kojima
Journal:  J Biol Chem       Date:  2010-03-03       Impact factor: 5.157

10.  Acquired protein S deficiency in a patient with systemic lupus erythematosus causing central retinal vein thrombosis.

Authors:  H M Prince; P J Thurlow; R C Buchanan; K M Ibrahim; P J Neeson
Journal:  J Clin Pathol       Date:  1995-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.